At a glance
What is it—and why does it matter?
Teriparatide is described as an injectable analog of parathyroid hormone, indicating it mimics PTH activity and is administered by injection. Mechanistically, teriparatide is a fragment identical to part of human parathyroid hormone, promoting osteoblast-mediated bone formation and affecting calcium handling (absorption and urinary loss). In this cohort comparison after mandibular fracture fixation, time to being pain-free differed between groups: 3rd post-operative day with teriparatide exposure versus 7th post-operative day without exposure (p < 0.001). Reported common adverse reactions (frequency stated as may affect more than 1 in 10 people) include nausea, limb pain, headache, and dizziness.
Each sentence above is copied from a published claim presentation. The links open its evidence record.
Treatment is reserved for specified patients at high fracture risk or those who failed or cannot tolerate other osteoporosis therapy. [1]Regulatory labelForteo prescribing informationDailyMed label updated June 2025 for teriparatide injection.
Identity + structure
A molecule, not a product name.
| Preferred name | Teriparatide | Ingredient |
|---|---|---|
| Pharmacologic class | Parathyroid hormone analog | Profile record |
| Peptide structure | 34 amino acids | Profile record |
| Also indexed as | teriparatide · rhPTH(1-34) · PTH 1-34 | Search aliases |
Mechanism + clinical pharmacology
Target, response, and disposition.
Activates PTH1 receptors. Intermittent exposure favors osteoblast activity and new bone formation, increasing skeletal mass and strength. [1]Regulatory labelForteo prescribing informationDailyMed label updated June 2025 for teriparatide injection.
Evidence ledger
What the evidence says.
These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.
Study findings
What studies observed in defined populations, comparators, and time periods.
In this study, observed clinical fracture rates were numerically lower with teriparatide than with alendronate at Weeks 24 and 48, though reported P values were P> 0.05 for both comparisons.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Gut microbiome composition changed in both intervention groups, with alterations primarily affecting short-chain fatty acid (SCFA)-producing taxa.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this ovariectomy rat model, intermittent PTH1-34 counteracted the Ovx-induced losses in trabecular structure, apparent volumetric BMD, and mechanical strength.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Compared with alendronate, teriparatide produced higher hip BMD at both Week 24 and Week 48, with statistical significance reported at Week 48 (P< 0.001) but not at Week 24 (P> 0.05).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The background states that anabolic osteoporosis therapies (including teriparatide) have demonstrated efficacy for increasing bone mineral density and lowering fracture risk.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an observational cohort of pregnancy- and lactation-associated osteoporosis (PLO), postpartum timing of teriparatide initiation was associated with magnitude of BMD response, with < 12 months postpartum initiation showing two-threefold larger BMD increases than ≥ 12M postpartum initiation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In postmenopausal women with osteoporosis, teriparatide injection lowers the risk of spine and non-spine fractures.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In an experimental mouse periodontitis model induced by ligature, iPTH treatment was associated with significantly less alveolar bone loss, consistent with an anabolic/protective effect on alveolar bone in this model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is described as requiring intermittent exposure for efficacy; this implies frequent administration that may reduce long-term adherence.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this randomized trial, fracture risk was not reduced versus standard care, even though BMD increased significantly in the intervention group.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this observational comparison, continuous subcutaneous PTH(1-34) infusion was associated with increased serum calcium relative to standard of care, with statistical significance reported as P < .001.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study defined all-cause mortality as the primary endpoint for the romosozumab-versus-teriparatide comparison.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After a single acute administration, PTH increased adipose-tissue thermogenic gene expression, with the magnitude depending on the dose.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a placebo-controlled trial in postmenopausal osteoporosis, teriparatide 20 mcg subcutaneously once daily (with calcium/vitamin D) lowered incidence of ≥1 new radiographic vertebral fracture compared with calcium/vitamin D alone.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide Sun is used to treat osteoporosis in adults, including postmenopausal women and men at increased fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
When strontium was combined with PTH1-34, maximum force (a bone material/mechanical property) increased relative to PTH1-34 alone (+ 18.2%).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pain scores (VAS) improved in both cohorts, with no statistically significant between-group difference reported (P= 0.282).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract summarizes that improvements are frequently reported, yet emphasizes methodological limitations (descriptive evidence, heterogeneity, and confounding by concomitant treatments), so efficacy and standard-of-care status are not established.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this timing-stratified observational cohort, the < 12M postpartum initiation group started with lower baseline BMD than the ≥ 12M postpartum initiation group.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion characterizes adjuvant teriparatide as efficacious for preventing non-union and eliminating delayed union in surgically fixed osteoporotic fracture patients.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With repeated daily exposure, PTH did not produce sustained adipose browning (i.e., the browning response was not maintained).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across both postpartum initiation strata, teriparatide use was associated with statistically significant increases in BMD.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pooled results found no statistically significant difference between teriparatide and control for Radiological Union Score for Hip, with confidence intervals spanning no effect.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In matched cohorts, adding teriparatide to ongoing denosumab produced a larger reduction in MRI-derived VBQ (percentage change) over 12 months than switching after denosumab withdrawal, with a statistically significant adjusted between-group difference.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using teriparatide initiation as the comparator in a matched cohort, romosozumab initiation was associated with a reduced hazard for spine or hip fracture (HR 0.63; 95% CI 0.55-0.72).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide Sun is also used for osteoporosis linked to long-term glucocorticoid use in men and women at increased fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
During continuous subcutaneous PTH(1-34) infusion, fractional calcium excretion was reported to be approximately 8% lower than under standard of care, with P = .014.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this retrospective cohort of SOT recipients receiving teriparatide, BMD increased significantly at multiple skeletal sites with reported percent changes and p-values.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across randomized controlled trials in older men with primary or secondary osteoporosis, teriparatide was associated with modest increases in bone mineral density; however, its effect on fracture risk was not consistent across studies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a 4-patient APECED-associated hypoparathyroidism case series with 4-15 mo follow-up, palopegteriparatide was associated with a strong calcemic response, alongside large serum-calcium variability during titration.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The reported QCT T-score shifted upward (less negative) following 18 months on the teriparatide+denosumab regimen, with p < 0.001.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The primary endpoint focused on incident fractures confirmed by imaging, with blinded adjudication to reduce assessment bias.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Relative risk reduction for new vertebral fracture over 19 months is reported as 65% for Forsteo compared with placebo.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In an ex vivo neonatal mouse calvaria formation assay, CHEMBL525610 was tested at 0.001 uM and assessed after 7 days relative to control; total bone area increased with reported Activity = 48.0%.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this comparative cohort, the TDco regimen (teriparatide combined with denosumab) showed a higher 1-year incidence of radiographic bone bridge effect than anti-resorptive monotherapies reported (denosumab or bisphosphonate).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this propensity score-matched real-world comparison, romosozumab initiation showed a lower hazard of spine or hip fracture versus teriparatide initiation (HR, 0.63; 95% CI, 0.55-0.72) over follow-up limited to 3 years.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort, combining teriparatide with denosumab was associated with a greater annual change in BMD than the other compared medication strategies reported in the abstract.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For women initiating teriparatide ≥ 12M postpartum, 12M BMD gains were reported at lumbar spine, total hip, and femoral neck, each statistically significant at p < 0.05.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a single adult HPP case during teriparatide therapy, BMD showed no change and fractures were not observed over the treated interval (observational within-case finding).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this rat model, adding strontium to PTH1-34 increased both apparent and tissue-level volumetric BMD compared with PTH1-34 alone (+ 9.6% and 6.7%).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adding strontium to PTH1-34 increased working energy (a mechanical/material property) compared with PTH1-34 alone (+ 17%).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When outcomes were analyzed per spinal level, perioperative teriparatide exposure was associated with reduced radiographic nonunion (RR 0.55; 95% CI 0.37-0.82; p= 0.004).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The included evidence base totaled 20 studies and 2543 patients spanning degenerative lumbar disease, adult spinal deformity, and osteoporotic vertebral fracture populations.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Postpartum timing modified the magnitude of 12M BMD response to teriparatide in PLO, with larger gains in the < 12M postpartum initiation group across LS, TH, and FN.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The indication statement includes fracture-risk reduction for both vertebral and nonvertebral fractures in postmenopausal osteoporosis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this randomized comparison, the fracture incidence proportions were similar between groups, with an estimated hazard ratio close to 1 and confidence interval spanning potential benefit and harm.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
With repeated daily administration, PTH increased weight gain, and the abstract attributes this primarily to increased food intake.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this propensity score-matched real-world comparison, romosozumab initiation showed a lower hazard of any osteoporotic fracture versus teriparatide initiation (HR, 0.68; 95% CI, 0.61-0.77) over follow-up limited to 3 years.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion states that the specified teriparatide+denosumab dosing schedule was associated with improved trabecular bone density in the studied group.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract states an association between MRONJ and antiresorptive and antiangiogenic therapies, framing MRONJ as a challenging complication.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this propensity score-matched real-world cohort, teriparatide initiation served as the comparator; romosozumab initiation showed a lower hazard of any osteoporotic fracture (HR 0.68; 95% CI 0.61-0.77).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For women initiating teriparatide < 12M postpartum, 12M BMD gains were reported at lumbar spine (LS), total hip (TH), and femoral neck (FN), each statistically significant at p < 0.01.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Clinically, teriparatide is used as an osteoporosis treatment for patients at high risk of fracture.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For postmenopausal osteoporosis, teriparatide is stated to reduce both vertebral and nonvertebral fracture risk.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
In a single adult HPP case, teriparatide exposure was associated with increased serum ALP during treatment, with reversal to baseline after cessation (within-person temporal association).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across included studies, perioperative teriparatide exposure was associated with reduced PJK risk versus no teriparatide (RR 0.40; 95% CI 0.22-0.75; p= 0.004).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
After statistical adjustment for baseline BMD, the observed difference in BMD response between postpartum timing groups persisted.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The evidence base summarized in this systematic review consisted of eighteen studies with 94 pediatric patients.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In an ovariectomized C57BL/6 mouse model, CHEMBL525610 was evaluated for anti-osteoporosis effects; micro-CT BV/TV increased relative to control after daily subcutaneous dosing (25 ug/kg) for 6 weeks, with reported Activity = 81.68%.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Under repeated daily dosing, PTH did not improve measures of insulin resistance or hyperglycemia in this model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adjuvant teriparatide was associated with lower delayed union incidence than standard therapy (0% vs 13.33%), with P = 0.0030.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In primary osteoblast cultures, exposure to PTH1-34 increased Rankl and decreased Opg gene expression; the abstract states this occurred whether PTH1-34 was administered alone or with strontium.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the teriparatide-treated group, specific gut microbial genera (Dubosiella and Butyrivibrio) showed significant enrichment in relative abundance.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this Taiwan nationwide cohort, prior AOM exposure within 2 years before teriparatide initiation showed no statistically significant association with fracture-related hospitalizations compared with no prior AOM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort study, the proportion completing the scheduled teriparatide treatment by 12 months was 52.9%.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This PLO Registry observational study followed teriparatide initiators with serial BMD measurements at baseline, 6M, and 12M, stratified by postpartum initiation timing (< 12M vs ≥ 12M).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In pooled analysis, perioperative teriparatide exposure was associated with reduced radiographic nonunion when analyzed per patient (RR 0.66; 95% CI 0.47-0.93; p= 0.02).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the matched cohort comparison, vertebral fractures occurred less often in the romosozumab group than the teriparatide group, with a hazard ratio below 1 and a 95% confidence interval excluding 1.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort of teriparatide initiators, prior AOM exposure within 2 years was associated with a reduced hazard for spinal fracture-related hospitalization compared with no prior AOM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Adding strontium to PTH1-34 increased trabecular thickness relative to PTH1-34 alone (+ 8.9%) in the ovariectomized rat model.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a single patient case, a 2-year course of teriparatide was associated with a significant increase in BMD, which the authors state enabled subsequent surgical fixation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the second case, a 6-month exposure to teriparatide did not change BMD as reported by the authors (BMD remained stable).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Functional disability (ODI) improved in both the teriparatide cohort and the normal-BMD cohort, with no statistically significant between-group difference (P= 0.447).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this trial, once-weekly teriparatide produced a greater Week 48 gain in L1–L4 lumbar spine BMD than weekly alendronate (5.01% vs 4.20%), with a mean difference of 0.80% (P= 0.025).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Clinical trial evidence in postmenopausal osteoporosis: 20 mcg SC once daily lowered the incidence of ≥1 new radiographic vertebral fracture versus placebo, with reported absolute and relative risk reductions.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Within the teriparatide-treated group, pre/post comparison showed statistically significant increases in lumbar spine and hip BMD after treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Continuous subcutaneous PTH(1-34) infusion was associated with decreased serum phosphate relative to standard of care, with P < .001 reported.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this cohort comparison after mandibular fracture fixation, time to being pain-free differed between groups: 3rd post-operative day with teriparatide exposure versus 7th post-operative day without exposure (p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A meta-analysis synthesized randomized controlled trials and observational studies to assess associations between perioperative teriparatide exposure and postoperative complications after spinal fusion.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the ligature-induced mouse periodontitis model, iPTH treatment improved measures of trabecular microarchitecture (specific parameters not provided in the abstract).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Within the phase 2 trial dataset analyzed here, teriparatide was associated with a mean percent increase in shear bone strength at Month 12 versus baseline, with a reported 95% confidence interval.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Between-group comparison indicated teriparatide produced a larger increase in the bone formation marker osteocalcin than denosumab, with P < 0.001.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
When expressed relative to the age-specific 95th percentile, urinary calcium/creatinine ratios were lower during continuous subcutaneous PTH(1-34) infusion than during standard of care (P < .001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a single patient case, teriparatide was used as an osteological co-treatment intended to support bone healing; BMD rose significantly, yet the nonunion did not resolve.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Comparative evidence
How the studied intervention compared with another intervention, comparator, or threshold.
In this real-world, propensity score–matched cohort study, the hazard of all-cause mortality was lower with romosozumab compared with teriparatide (hazard ratio 0.68 with a 95% confidence interval of 0.49-0.94).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Propensity score matching created a 1:1 matched cohort in which the teriparatide initiator group included 8616 patients; administrative follow-up was capped at 3 years.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis used propensity score matching at a 1:1 ratio, resulting in equal-sized cohorts (60 vs 60) for combination versus sequential teriparatide initiation strategies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analyzed phase 2 trial reports a statistically significant between-treatment difference in Month 12 percent change in shear bone strength, favoring romosozumab over teriparatide (p<.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This study analyzed CT imaging from an existing randomized clinical trial in which teriparatide was one of the randomized treatment arms, alongside romosozumab and placebo, over 12 months in postmenopausal women with low BMD.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Eligibility criteria specified systematic reviews with meta-analyses evaluating romosozumab versus teriparatide in postmenopausal osteoporosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The stated objective was a real-world comparative assessment of all-cause mortality between romosozumab and teriparatide in osteoporosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Meta-analysis in pediatric hypoparathyroidism found lower serum phosphate with teriparatide versus conventional therapy, with a negative weighted mean difference (WMD -0.28, 95% CI -0.45 to -0.12).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion states that perioperative teriparatide use in low-BMD patients was associated with outcomes comparable to those seen in a normal-BMD cohort for clinical, radiographic, and complication measures.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
For regulatory comparison, Teriparatide Sun’s reference product is Forsteo.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The complication outcomes listed (pseudarthrosis, proximal junctional kyphosis, reoperation) were reported as not significantly different between the teriparatide (anabolic users) and normal-BMD cohorts, with the stated percentages.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A head-to-head comparative clinical design (non-randomized, open-label) evaluated subcutaneous teriparatide dosing at 20 μg daily versus subcutaneous denosumab 60 mg every six months, with co-supplementation of calcium and vitamin D, and measured BMD, bone turnover markers, and 16S rDNA-based gut microbiota changes over a six-month period.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
To reduce baseline differences between treatment groups, the study performed propensity score matching in a 1:1 ratio for romosozumab versus teriparatide initiators.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Propensity score matching created two balanced cohorts (1:1): 60 receiving teriparatide added to ongoing denosumab and 60 switching to teriparatide after denosumab withdrawal.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Because denosumab-associated cases were fewer relative to bisphosphonate exposure, the literature summarized here did not allow a determination of differential effectiveness across antiresorptive classes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A retrospective cohort evaluated two teriparatide initiation strategies after long-term denosumab—concurrent (combination) vs post-withdrawal (sequential)—using MRI-derived vertebral bone quality (VBQ) score to assess bone marrow microenvironment (marrow adiposity).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide served as the active comparator arm in a target-trial emulation assessing incident dementia in people with osteoporosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The comparator arm allowed other bone-targeted medicines but did not permit teriparatide or other anabolic agents.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the study’s stated conclusion, romosozumab initiation had lower observed fracture incidence compared with teriparatide initiation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In a randomized, double-blind, controlled study of glucocorticoid-treated adults with osteoporosis, daily teriparatide produced a larger percent increase in lumbar-spine BMD than daily alendronate at the last measurement.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this matched cohort analysis, the comparative effectiveness between romosozumab and teriparatide was not statistically different for non-vertebral and hip fracture outcomes.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The stated objective was an evidence summary comparing romosozumab versus teriparatide on efficacy and safety outcomes in postmenopausal osteoporosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This clinical research was a randomized, double-blind, controlled comparison of teriparatide versus alendronate in glucocorticoid-exposed patients with osteoporosis.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
After multiple-comparison adjustment (Holm), the comparison of romosozumab vs teriparatide for scheduled-treatment completion at 12 months remained statistically significant (p = 0.016).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In severe osteoporosis, teriparatide was reported to significantly reduce vertebral fracture risk versus the bisphosphonate risedronate.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A retrospective cohort using target trial emulation compared romosozumab versus teriparatide in propensity-score–matched adults with osteoporosis and chronic kidney disease defined by eGFR <60 mL/min/1.73 m2.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the subgroup aged ≥ 60 years, the hazard of all-cause mortality was lower for romosozumab compared with teriparatide (HR 0.65, 95% CI 0.47-0.88).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mechanism
Source-backed statements about targets, pathways, and biological response.
With intermittent (once-daily) systemic exposure, teriparatide produces anabolic skeletal effects by favoring osteoblast-mediated bone formation over osteoclast-mediated resorption.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In HKRKB7 cells expressing human PTHR1, CHEMBL525610 produced agonist activity measured as intracellular cAMP accumulation after 20 mins; potency was EC50 = 2.5 nM by enzyme immunoassay.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide affects calcium handling by increasing dietary calcium absorption and reducing excessive urinary calcium loss.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Mechanistically, teriparatide is a fragment identical to part of human parathyroid hormone, promoting osteoblast-mediated bone formation and affecting calcium handling (absorption and urinary loss).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A Cre-lox strategy is described: Col1A1 promoter drives Cre recombinase to delete a floxed MCP1 allele in the osteoblast/osteocyte lineage.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The stated research question was whether teriparatide could promote healing of mandibular fractures.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The cohort design matched treatment initiators by calendar time: for each romosozumab initiator, a teriparatide initiator was selected within the same month ± 3 months.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Beyond changing cytokine and T-cell markers, iPTH altered tissue-level spatial relationships by reducing the periodontitis-associated increase in FOXP3–IL-17 spatial proximity (measurement method not detailed in the abstract).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Intermittent (once-daily) systemic exposure to teriparatide promotes anabolic skeletal effects, preferentially increasing osteoblast-driven bone formation relative to osteoclast-mediated resorption.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The abstract links PTH to increased ghrelin production in the stomach and increased AgRP expression in the hypothalamus, consistent with orexigenic (appetite-stimulating) signaling.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Intermittent (once-daily) systemic exposure to teriparatide is described as anabolic in bone, preferentially increasing osteoblast-driven bone formation relative to osteoclast-driven resorption.
5 cited sources · 5 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 5 source records.
The findings indicate iPTH immunomodulation of the Treg/Th17 axis in this mouse model: increased regulatory T-cell representation (cervical lymph nodes) and FOXP3 (a Treg-associated transcription factor), with concurrent suppression of IL-17 in gingival tissue.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Taking teriparatide once daily stimulates new bone formation by favoring osteoblast activity over osteoclast activity.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In a cell-based assay using HEK293 cells overexpressing PTH1R, CHEMBL525610 acted as an agonist measured by intracellular cAMP production; potency was reported as EC50 = 0.3 nM.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Mouse lineage-tracing, single-cell transcriptomics, and conditional genetics indicate that intermittent PTH (teriparatide) promotes osteogenesis from CAR mesenchymal progenitors through combined cell-intrinsic changes and cell-extrinsic niche effects.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The research question was whether pre-teriparatide AOM exposure modifies subsequent fracture risk outcomes in very-high-fracture-risk patients starting teriparatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study’s primary endpoint was major osteoporotic fracture hospitalization assessed within a 3-year window in a cohort of teriparatide initiators.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide corresponds to a fragment of human parathyroid hormone and promotes bone formation via effects on osteoblast (bone-forming) cells.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this mouse periodontitis model, iPTH shifted bone remodeling markers toward formation by enhancing osteoblast activity and suppressing osteoclastogenesis (no quantitative details provided in the abstract).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Background frequency of mechanical complications after adult spinal deformity surgery is reported as 15 to 40 percent.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Functional testing using Treg depletion indicates a Treg-dependent component to iPTH’s bone protection in this model; removing Tregs reduced iPTH’s protective effect on bone (specific outcomes not quantified here).
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The design included pair-feeding to control caloric intake, aiming to distinguish direct PTH effects from effects mediated by increased food intake.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Pharmacokinetics
How the studied compound is absorbed, distributed, metabolized, and cleared.
After an under-the-skin injection, teriparatide’s absolute bioavailability is about 95% (from pooled 20, 40, and 80 mcg data).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
PK summary: high SC bioavailability (~95% from pooled 20-, 40-, 80- mcg data); rapid absorption with Tmax ~30 minutes for 20 mcg and concentrations falling below quantification within 3 hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Severe renal impairment altered teriparatide pharmacokinetics: higher systemic exposure (AUC) and longer half-life (T1/2), without increased Cmax, in a small sample (n=5).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide is well absorbed subcutaneously, with reported absolute bioavailability ~95% derived from pooled dose-ranging data (20-, 40-, 80- mcg).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Severe renal impairment was associated with higher overall exposure (AUC) and longer half-life (T1/2), without an increase in Cmax in the reported patients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A human ADMET entry reported oral bioavailability for CHEMBL525610 as F = 95.0 %.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Severe renal impairment (CrCl<30 mL/minute) was associated with higher systemic exposure (AUC) and longer half-life (T1/2) for teriparatide, without an increase in maximum serum concentration, in a small sample (n=5).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Structural data indicate receptor-bound PTH(1-34) adopts a fully α-helical conformation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Safety findings
Observed or labeled risks, adverse effects, and safety signals.
Short-term clinical pharmacology data in healthy volunteers report symptomatic orthostatic hypotension episodes occurring transiently in 5% after teriparatide dosing.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Only the most common side effects listed in this section are captured; the full list is referenced but not included here.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Reported common adverse reactions (frequency stated as may affect more than 1 in 10 people) include nausea, limb pain, headache, and dizziness.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
A short-term clinical pharmacology safety observation in healthy volunteers found a 5% incidence of transient symptomatic orthostatic hypotension after teriparatide injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Because teriparatide can increase serum calcium, it may induce hypercalcemia or worsen it when hypercalcemia is already present.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In short-term studies in healthy volunteers, 5% had brief symptomatic orthostatic hypotension with teriparatide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In short-term studies in healthy volunteers, 5% had transient symptomatic orthostatic hypotension, usually starting within 4 hours after dosing and resolving within minutes to hours without treatment.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label limits consideration of lifetime exposure beyond 2 years to patients who remain at, or return to, high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Post-approval reports include hypercalcemia greater than 13 mg/dL associated with teriparatide use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Short-term pharmacology studies reported transient symptomatic orthostatic hypotension after dosing, with onset typically within 4 hours and spontaneous resolution within minutes to hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Immunogenicity assessment in a postmenopausal osteoporosis clinical trial detected cross-reactive anti-teriparatide antibodies in 3% of treated women (15/541).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Short-term pharmacology studies in healthy volunteers reported a 5% incidence of transient symptomatic orthostatic hypotension after dosing, with onset typically within 4 hours and spontaneous resolution over minutes to hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Postmarketing observational human data summarized in the warning indicate no observed increase in osteosarcoma risk, though this does not establish causality or eliminate risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Immunogenicity testing in a 24-week randomized trial found detectable anti-drug antibodies in 2.2% (2/90) of subjects on teriparatide injection.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label warns of a hypercalcemic effect and potential exacerbation in patients who already have elevated serum calcium.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Short-term clinical pharmacology data in healthy volunteers report symptomatic orthostatic hypotension at 5%, with onset within 4 hours post-dose and spontaneous resolution within minutes to hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Immunogenicity testing in a 24-week randomized comparison found detectable anti-drug antibodies in 2.2% (2/90) of BONSITY recipients; among antibody-positive BONSITY subjects, 1 developed neutralizing antibodies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Overdose experience described in postmarketing reports includes accidental single-dose delivery of up to 800 mcg (40× recommended), associated with transient symptoms (nausea, weakness/lethargy, hypotension) and no reported overdose-related fatalities.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Short-term clinical pharmacology data in healthy volunteers reported symptomatic orthostatic hypotension episodes in 5%, described as transient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Postapproval spontaneous reports include cases of marked hypercalcemia (>13 mg/dL) during teriparatide injection use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The warning notes a hypercalcemic effect and potential aggravation of baseline hypercalcemia in patients who already have elevated calcium.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
A short-term clinical pharmacology signal is described: symptomatic orthostatic hypotension occurred transiently in 5% of healthy volunteers, with onset within 4 hours post-dose and spontaneous resolution.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Immunogenicity was observed: a small proportion of treated postmenopausal women had detectable cross-reactive antibodies to teriparatide during a clinical trial.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Short-term clinical pharmacology data in healthy volunteers reported symptomatic orthostatic hypotension in 5%, described as transient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This percentage comes from short-term clinical pharmacology studies in healthy volunteers; timing and resolution are described in the same section.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Nonclinical safety signal: teriparatide exposure in rats was associated with increased osteosarcoma incidence.
2 cited sources · 2 regulatory records
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
This rate comes from short-term clinical pharmacology studies in healthy volunteers; it may not reflect incidence in patients with osteoporosis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Nonclinical findings in both sexes of rats indicated higher osteosarcoma incidence with teriparatide exposure.
3 cited sources · 3 regulatory records
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Short-term studies in healthy volunteers reported transient symptomatic orthostatic hypotension (5%), with onset typically within 4 hours post-dose and spontaneous resolution within minutes to hours.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindications
Circumstances in which a specific product label says it should not be used.
Contraindication: prior severe hypersensitivity to teriparatide or any inactive excipient in FORTEO.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label lists a contraindication: prior severe hypersensitivity to teriparatide or any excipient in the product.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Hypersensitivity to teriparatide or any excipient is a contraindication.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A labeled contraindication is known hypersensitivity to the active drug (teriparatide) or any excipient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
Contraindications listed include specific bone diseases (Paget’s disease, bone cancer, bone metastases), history of skeletal radiation therapy, hypercalcaemia, unexplained elevated alkaline phosphatase, and severe kidney disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is contraindicated for patients with known hypersensitivity to the active drug or any excipient.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
A labeled contraindication is hypersensitivity to teriparatide or any excipient (including prior reactions such as angioedema/anaphylaxis).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label also notes examples of hypersensitivity reactions, but the contraindication is based on hypersensitivity status.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A labeled contraindication is hypersensitivity to the active peptide or any excipient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use Teriparatide Injection if the patient is allergic to teriparatide or its ingredients; reported reactions include angioedema and anaphylaxis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Labeled contraindication: hypersensitivity to the active peptide or any excipient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Use is contraindicated in pregnancy and during breastfeeding.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use Teriparatide Injection if you are allergic to teriparatide or any ingredient in the product.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use FORTEO in people with a history of severe allergy to teriparatide or its inactive ingredients.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The contraindication is hypersensitivity to the active peptide or formulation components; reported reactions include angioedema and anaphylaxis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A labeled contraindication is hypersensitivity to teriparatide or any excipient (including reported angioedema/anaphylaxis).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindication: known hypersensitivity to teriparatide or any excipient in the formulation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Contraindication: known hypersensitivity to the active peptide (teriparatide) or formulation excipients.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Do not use teriparatide injection if a patient is hypersensitive to teriparatide or any excipient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use teriparatide injection if you are allergic to teriparatide or its ingredients; reactions have included angioedema and anaphylaxis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Do not use BONSITY in people allergic to teriparatide or its ingredients; reported reactions include angioedema and anaphylaxis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Listed contraindications include specific bone diseases/malignancy, prior skeletal radiotherapy, hypercalcaemia, unexplained elevated alkaline phosphatase, and severe kidney disease.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled contraindication is hypersensitivity to the active peptide or any formulation excipient.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Interactions
Source-backed product and drug interaction statements.
Because teriparatide can temporarily raise calcium, clinicians should consider signs of digitalis toxicity when BONSITY is used with digoxin.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status
Product-, indication-, and jurisdiction-specific regulatory records.
Teriparatide injection has an approved indication for glucocorticoid-induced osteoporosis in adults receiving sustained systemic glucocorticoids at prednisone-equivalent doses ≥5 mg/day, when fracture risk is high or other therapies are not suitable.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
FORTEO is indicated for postmenopausal women with osteoporosis at high fracture risk (or who can’t use other therapies) and it reduces vertebral and nonvertebral fractures in this group.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product labeling specifies that teriparatide injection is not an approved IV or IM formulation/route.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory conclusion: based on comparable quality and bioequivalence to Forsteo, the EMA supported EU authorisation.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled dosage form is a prefilled pen containing teriparatide solution at 250 mcg/mL (total 560 mcg/2.24 mL), designed to dispense 28 daily 20 mcg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In postmenopausal women with osteoporosis who are at high fracture risk (or unable to use other therapies), teriparatide injection is an approved therapy and is stated to reduce vertebral and nonvertebral fractures.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide Injection is used to treat postmenopausal women with osteoporosis at high risk for fracture (or who failed/can’t tolerate other therapies) and it reduces vertebral and nonvertebral fractures in this group.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling restricts approved routes, excluding intravenous and intramuscular administration.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes postmenopausal osteoporosis in women at high fracture risk, including those with prior osteoporotic fracture or multiple risk factors, or those who failed/intolerant to other therapies.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 2 source records.
The label places a lifetime-duration consideration: treatment beyond 2 years is only to be considered when the patient remains at, or returns to, high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The EMA description classifies Teriparatide Sun as a hybrid medicine: it shares the same active substance as its reference product but differs in some respects.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide Injection is used to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture (or who failed/can’t tolerate other therapies).
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
This labeled indication covers postmenopausal osteoporosis in patients at high fracture risk (e.g., prior osteoporotic fracture or multiple risk factors) and those unable to use other osteoporosis therapies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling limits lifetime teriparatide exposure beyond 2 years to situations where high fracture risk persists or recurs.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using teriparatide for more than 2 years over a lifetime should only be considered for patients who remain (or again become) at high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes treating postmenopausal osteoporosis in patients at high fracture risk, including those with prior osteoporotic fracture or multiple risk factors, or those who failed/are intolerant to other osteoporosis therapies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling places a lifetime treatment-duration consideration: beyond 2 years should be considered only when the patient is still (or again) at high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide injection has an approved indication for increasing bone mass in men with primary/idiopathic or hypogonadal osteoporosis at high fracture risk, including those who cannot use other osteoporosis therapies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Regulatory status: the European Commission granted Forsteo a marketing authorisation valid throughout the European Union dated 10 June 2003.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label sets a lifetime treatment-duration consideration: >2 years only when fracture risk is high again or still high.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
FORTEO is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high fracture risk (or who can’t use other therapies).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes postmenopausal osteoporosis in patients at high fracture risk (or failed/intolerant to other therapy), with a stated effect of reducing vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeling limits routine lifetime exposure to 2 years, with extension only considered for persistent or recurrent high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide Injection is used to treat osteoporosis in men and women taking sustained systemic glucocorticoids (equivalent to 5 mg or more prednisone daily) who are at high risk for fracture (or who failed/can’t tolerate other therapies).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
FORTEO is indicated for men and women with osteoporosis due to long-term systemic glucocorticoids (≥5 mg prednisone-equivalent daily) who are at high fracture risk or can’t use other therapies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This labeled use applies to postmenopausal women with osteoporosis meeting the product’s criteria for “high risk for fracture,” or with failure/intolerance to other therapies.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Teriparatide injection has an approved indication for postmenopausal osteoporosis in patients at high fracture risk, including those with prior fracture/multiple risk factors or who cannot use other therapies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled indication includes postmenopausal osteoporosis in patients at high fracture risk (e.g., prior osteoporotic fracture or multiple risk factors) or those who failed/intolerant to other therapies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label limits routine lifetime exposure to 2 years, with extension only for persistent/recurring high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration
Product-specific route, timing, formulation, and use instructions—not universal dosing advice.
Treatment duration is limited to up to two years total, with a single lifetime course recommended.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The label limits lifetime exposure: treatment beyond 2 years is only to be considered when the patient remains at, or returns to, high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Forsteo comes as a solution for injection in prefilled pens; one 2.4 ml pen has 600 micrograms of teriparatide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration route and sites for teriparatide injection are subcutaneous, typically in the thigh or abdominal region.
4 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 4 source records.
Using FORTEO for more than 2 years in a lifetime should only be considered if fracture risk remains high or becomes high again.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Throw away the teriparatide pen 28 days after first use.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product presentation is an injectable solution supplied in prefilled pens with 600 micrograms teriparatide per 2.4 ml pen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using teriparatide for more than 2 years in a lifetime should only be considered if fracture risk remains high or becomes high again.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosage form is a prefilled single-patient-use pen containing 560 mcg in 2.24 mL (250 mcg/mL), designed for 28 daily 20 mcg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Administration per product overview: a pre-filled pen delivers 20 micrograms daily via subcutaneous injection to the thigh or abdomen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dosage form: teriparatide injection in a single-patient-use prefilled pen designed to deliver 28 once-daily 20 mcg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label limits routine lifetime exposure: treatment beyond 2 years should be considered only for patients who remain at, or return to, high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The product is supplied as an injectable solution in a prefilled pen device, with 600 micrograms of teriparatide per 2.4 ml pen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label sets a lifetime treatment-duration consideration: >2 years of teriparatide should only be considered for patients who remain at or return to high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dosage form/strength: prefilled pen containing teriparatide solution at 250 mcg/mL (total 560 mcg/2.24 mL), designed to dispense 20 mcg daily for 28 doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
A prefilled pen contains 560 mcg/2.24 mL (250 mcg/mL) and is intended to give 28 daily 20 mcg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dosing guidance specifies 20 micrograms administered once per day by subcutaneous injection, with injection sites including thigh or abdomen.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosage form is a prefilled pen containing teriparatide solution at 250 mcg/mL (560 mcg/2.24 mL) designed for 28 once-daily 20 mcg injections.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide Sun comes as a pre-filled pen and can be self-injected after training.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Treatment duration guidance: lifetime use beyond 2 years should be considered only for patients who remain at or return to high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Treatment duration is limited: use up to 2 years total, and the course should not be repeated within a patient’s lifetime.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled injection sites for subcutaneous administration are the thigh or abdominal region.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record.
The label places a lifetime treatment-duration consideration: beyond 2 years only when high fracture risk persists or recurs.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Dosage form/strength: prefilled single-patient pen containing teriparatide solution at 250 mcg/mL (total 560 mcg/2.24 mL), designed to deliver 28 daily 20 mcg doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Lifetime treatment beyond 2 years is to be considered only for patients who remain at, or return to, high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This states duration limits but does not explain reasons or exceptions.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Treatment duration guidance limits use to a maximum of two years and restricts patients to a single two-year course over their lifetime.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The labeled route restriction excludes intravenous and intramuscular administration; use is limited to subcutaneous injection.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
6 cited passages across 3 source records.
Dose records
Product- and indication-specific dose statements preserved separately to prevent unsafe generalization.
Label-recommended regimen is 20 mcg administered subcutaneously once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The usual dose is 20 mcg injected under the skin once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Label-recommended dosing for teriparatide injection is 20 mcg administered subcutaneously once per day.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Labeled dosing is a fixed 20 mcg subcutaneous daily dose.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Forsteo is recommended at 20 micrograms subcutaneously once daily, with injection sites including thigh or abdomen.
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 2 source records.
Label-recommended adult dosing is 20 mcg per day administered subcutaneously.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Recommended dose: 20 mcg subcutaneously once daily.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using Teriparatide Injection for more than 2 years over a lifetime should only be considered if the person is (again) at high risk for fracture.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Recommended teriparatide dosing for FORTEO is 20 mcg administered subcutaneously once daily.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
4 cited passages across 3 source records.
The recommended regimen is 20 mcg teriparatide administered subcutaneously once per day.
3 cited sources · 3 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
3 cited passages across 3 source records.
Recommended adult dosing for teriparatide injection is 20 micrograms administered subcutaneously once daily.
4 cited sources · 4 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 4 source records.
Standard adult dosing for teriparatide (BONSITY) is 20 mcg administered via subcutaneous injection once per day.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The label limits lifetime exposure: treatment beyond 2 years is only to be considered for persistent or recurrent high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using teriparatide for more than 2 years in a person’s lifetime should be considered only if they still have (or again have) high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Label-recommended teriparatide dosing is 20 mcg subcutaneously once daily.
5 cited sources · 5 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 5 source records.
The label limits lifetime exposure: treatment beyond 2 years should only be considered when the patient remains at, or returns to, high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Using teriparatide for more than 2 years over a lifetime should only be considered if the person is (or again becomes) at high fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The stated treatment duration limit is up to two years total, with a lifetime limit of one two-year course.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Studied populations
Who was represented in a study, label, or registry record.
One indicated population for Forsteo in osteoporosis is women after menopause.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
An indicated population is men with osteoporosis who have increased fracture risk.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
FORTEO (teriparatide) is indicated for postmenopausal osteoporosis in patients at high fracture risk or with failure/intolerance of other osteoporosis therapies.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Indicated use includes glucocorticoid-associated osteoporosis in women and men who are at increased risk of fractures due to long-term glucocorticoid therapy.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Indicated adult populations include postmenopausal women with osteoporosis and men with osteoporosis who are at increased risk of fractures.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Identity
Ingredient, molecule, and product identity statements.
The review used a multi-database search through April 30, 2026 and synthesized outcomes using random-effects meta-analysis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is identified as recombinant human parathyroid hormone comprising amino acids 1-34 (hPTH [1-34]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is the 1-34 amino-acid fragment of parathyroid hormone (PTH).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is identified here as a synthetic peptide with primary clinical use in osteoporosis treatment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Forsteo’s active ingredient is teriparatide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide is a synthetic peptide corresponding to human PTH(1-34), matching the biologically active N-terminal region of the native 84-amino-acid hormone.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Among the listed synonyms for teriparatide is the name “Forteo”.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is a synthetic peptide corresponding to PTH(1-34), the biologically active N-terminal region of endogenous human PTH(1-84).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The reference product and Teriparatide Sun differ by active-substance production method (biological via bacteria versus chemical synthesis).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The dosage form is a single-patient-use prefilled pen containing a 250 mcg/mL teriparatide solution (560 mcg/2.24 mL), designed for 28 daily 20 mcg subcutaneous doses.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide is described as a synthetic peptide derived from parathyroid hormone (PTH).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is a manufactured peptide corresponding to PTH(1-34), the N-terminal bioactive region of endogenous human PTH(1-84).
2 cited sources · 2 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Teriparatide is a recombinant peptide corresponding to PTH(1-34), matching the biologically active N-terminal 34 amino acids of endogenous human PTH(1-84).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This source lists the molecular weight of teriparatide as 4117.79.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The investigators performed a systematic review and meta-analysis, synthesizing results across multiple studies.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is a recombinant parathyroid hormone fragment (PTH 1-34) described as an analog of PTH.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The peptide intervention is parathyroid hormone (PTH) 1-34, abbreviated as iPTH (intermittent PTH 1-34).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this trial report, teriparatide is identified as a parathyroid hormone analogue.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is engineered (recombinant) PTH(1-34), identical in sequence to the biologically active N-terminal 34 amino acids of endogenous human PTH(1-84).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The eligibility criteria for interventions in this systematic review explicitly included teriparatide among the anti-osteoporotic agents assessed in RCTs enrolling men with primary osteoporosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
One listed alternate name for teriparatide is “(1-34)-human parathyroid hormone”.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this rabbit model, PTH (1-34) was delivered via a one-time intra-articular (knee joint) injection.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is a recombinant PTH(1-34) analog that is sequence-identical to the biologically active N-terminal 34 amino acids of endogenous human PTH(1-84).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
This source reports teriparatide’s elemental composition as C181H291N55O51S2.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The synonym list for teriparatide includes the name “Forsteo”.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is recombinant PTH(1-34), identical to the biologically active N-terminal 34 amino acids of endogenous human PTH(1-84).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide is the 1-34 fragment of human parathyroid hormone and is chemically synthesized.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide is described as an injectable analog of parathyroid hormone, indicating it mimics PTH activity and is administered by injection.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is recombinant PTH(1-34), i.e., the biologically active N-terminal fragment of human parathyroid hormone, with an identical amino-acid sequence to the first 34 residues of PTH(1-84).
5 cited sources · 5 regulatory records
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
5 cited passages across 5 source records.
Teriparatide in BONSITY is recombinant PTH(1-34), identical in sequence to the biologically active N-terminal 34 amino acids of endogenous human PTH(1-84).
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Teriparatide is identified as a drug (used as a reference ligand in comparing receptor-trafficking behavior).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The product’s active ingredient is teriparatide.
1 cited source · 1 regulatory record
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
In this report, teriparatide is characterized as an osteoanabolic agent (i.e., bone-building therapy) and was given to two adult patients with mucopolysaccharidosis Type IVB for apparently low bone mineral density.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this source, teriparatide is classified as a protein under the “Molecule type” field.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is a peptide consisting of the N-terminal 34 amino acids of human parathyroid hormone (PTH).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is cataloged as a peptide ligand (Ligand ID 4448) and its International Nonproprietary Name (INN) is teriparatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is the parathyroid hormone fragment PTH 1-34.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source positions teriparatide as a commonly used pharmacologic therapy in postmenopausal osteoporosis management.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide corresponds to the parathyroid hormone (PTH) fragment PTH1-34.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Additional research & classification gaps
52 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (52)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Histologic evaluation with H&E did not show apparent differences in osteoclast or osteoblast cell numbers across groups.
Research context only—not evidence of a treatment effect.
- Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.
H&E staining showed no apparent differences in osteoclast or osteoblast numbers among those groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion states that the overall efficacy and safety profiles were similar between romosozumab and teriparatide.
Research context only—not evidence of a treatment effect.
- Romosozumab Versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: An Overview of Systematic Reviews With Direct and Indirect Meta-Analyses.
Romosozumab demonstrated efficacy and safety similar to teriparatide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In intention-to-treat follow-up to 2 years, romosozumab initiation was associated with lower incident dementia risk than teriparatide initiation, quantified by ARR 0.7% and RR 0.91.
Research context only—not evidence of a treatment effect.
- Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.
In the 2-year intention-to-treat analyses, the ARR was 0.7% (95% confidence interval, - 0.1 to 1.3%), with a RR of 0.91 (95% confidence interval, 0.84 to 1.01).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the authors’ conclusion, romosozumab initiation was associated with lower dementia risk—especially Alzheimer’s disease—relative to teriparatide initiation in an osteoporosis population.
Research context only—not evidence of a treatment effect.
- Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.
romosozumab initiation among individuals with osteoporosis may be associated with a lower risk of dementia, particularly Alzheimer's disease, than teriparatide initiation.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Relative to alendronate, teriparatide was described as producing comparable gains in lumbar spine bone mineral density (BMD), without a stated numeric difference.
Research context only—not evidence of a treatment effect.
- A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review.
increased lumbar spine BMD to a comparable extent as alendronate
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In per-protocol analysis at 1 year, Alzheimer’s disease risk was lower for romosozumab initiation than teriparatide initiation, with ARR 0.6% and RR 0.77.
Research context only—not evidence of a treatment effect.
- Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.
For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.3 to 0.9%), with an RR of 0.77 (95% confidence interval, 0.65 to 0.86).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In intention-to-treat follow-up to 2 years, Alzheimer’s disease risk was lower for romosozumab initiation than teriparatide initiation, with ARR 0.6% and RR 0.88.
Research context only—not evidence of a treatment effect.
- Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.
For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.0 to 1.1%), with an RR of 0.88 (95% confidence interval, 0.79 to 1.00).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this single-animal-per-group pilot, the PTH1.6 condition showed higher trabecular bone volume and mineral density than control.
Research context only—not evidence of a treatment effect.
- Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.
Trabecular bone volume and mineral density were higher in PTH1.6 than in controls
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In per-protocol analysis at 1 year, romosozumab initiation was associated with lower incident dementia risk than teriparatide initiation, with ARR 1.0% and RR 0.76.
Research context only—not evidence of a treatment effect.
- Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.
In the 1-year per-protocol analyses, the ARR was 1.0% (95% confidence interval, 0.7 to 1.4%), with a RR of 0.76 (95% confidence interval, 0.69 to 0.82).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this single-animal-per-group pilot, the PTH3.2 condition showed lower trabecular bone volume and mineral density than control.
Research context only—not evidence of a treatment effect.
- Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.
whereas PTH3.2 values were lower than controls
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion notes that the evidence base primarily relied on indirect comparisons for most outcomes, which can affect certainty of comparative estimates.
Research context only—not evidence of a treatment effect.
- Romosozumab Versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: An Overview of Systematic Reviews With Direct and Indirect Meta-Analyses.
with most outcomes assessed through indirect comparisons
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
By fluorescence labeling, the PTH1.6 condition had the greatest observed new bone formation among the groups.
Research context only—not evidence of a treatment effect.
- Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.
Fluorescence labeling demonstrated the greatest new bone formation in PTH1.6.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
It is unclear how intermittent teriparatide affects alveolar bone regeneration.
Research context only—not evidence of a treatment effect.
- Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.
its effects on alveolar bone regeneration remain unclear.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
This comparative effectiveness analysis specified time-bounded fracture endpoints: vertebral and non-vertebral fractures within 12 months as primary, and hip fractures as secondary, for the romosozumab–teriparatide comparison.
Research context only—not evidence of a treatment effect.
- pubmed-42584962
The primary effectiveness outcomes were non-vertebral and vertebral fractures within 12 months. The secondary outcome was hip fractures.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the pooled comparison versus control, teriparatide showed no statistically significant effect on delayed union, with an RR of 0·72 and wide confidence intervals crossing 1.
Research context only—not evidence of a treatment effect.
- The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis.
There were no significant differences between delayed union rates (RR 0·72, 95% CI 0·18 to 2·84; Z=0·48; p=0·63)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the authors’ interpretation of their analyses, teriparatide was not associated with delayed fracture healing.
Research context only—not evidence of a treatment effect.
- The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis.
Teriparatide does not appear to delay healing
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In the source, teriparatide is characterized as an anabolic (bone-building) therapy used for osteoporosis.
Research context only—not evidence of a treatment effect.
- Influence of bisphosphonate pretreatment on bone mineral density gains and fracture outcomes with teriparatide: A systematic review and meta-analysis.
Teriparatide is a potent anabolic therapy for osteoporosis
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract concludes that teriparatide effectively reduces vertebral fracture risk and improves bone mineral density (BMD) in postmenopausal osteoporosis, without specifying effect sizes.
Research context only—not evidence of a treatment effect.
- A Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review.
Teriparatide is effective in lowering vertebral fracture risk and enhancing BMD in postmenopausal osteoporosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The results indicate source-dependent differences in impurity composition/profile across teriparatide study materials.
Research context only—not evidence of a treatment effect.
- pubmed-42312586
Distinct impurity profiles were observed in the TPT study materials from different synthetic sources.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The reported trabecular bone density increased substantially during the 18-month teriparatide+denosumab combination regimen, with statistical significance noted (p < 0.001).
Research context only—not evidence of a treatment effect.
- Change in vBMD of Combination Therapy of Teriparatide and Denosumab in Osteoporosis at 18 Months: How Much Difference Does It Make on Spine vBMD?
the average trabecular bone density improved from 68.08 to 97.22 mg/cm3, a 54.9% increase (p < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Comparing materials derived from different synthetic sources, the impurity profile differed between sources.
Research context only—not evidence of a treatment effect.
- pubmed-42312586
Distinct impurity profiles were observed in the TPT study materials from different synthetic sources.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Timing of the reported QCT T-score assessment is stated as an average of 6 months after completing teriparatide treatment.
Research context only—not evidence of a treatment effect.
- Change in vBMD of Combination Therapy of Teriparatide and Denosumab in Osteoporosis at 18 Months: How Much Difference Does It Make on Spine vBMD?
the mean intra-treatment QCT T score (measured at an average of 6 months after completion of treatment with teriparatide)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this meta-analysis, the primary endpoint was proximal junctional kyphosis (PJK).
Research context only—not evidence of a treatment effect.
- pubmed-42590191
The primary pooled outcome was proximal junctional kyphosis (PJK).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The analysis also assessed radiographic nonunion, mechanical complications, reoperation, and incident new vertebral fractures as secondary endpoints.
Research context only—not evidence of a treatment effect.
- pubmed-42590191
Secondary outcomes were radiographic nonunion, mechanical complications, reoperation rate, and incidence of new vertebral fractures.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors interpret the available evidence as suggesting a possible reduction in time to union with teriparatide in osteoporotic fractures, while noting that additional prospective evidence is needed.
Research context only—not evidence of a treatment effect.
- The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis.
Teriparatide does not appear to delay healing and might reduce the time to union for osteoporotic fractures, although further prospective evidence is needed.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The evidence base synthesized in the review consisted of 22 economic evaluation studies.
Research context only—not evidence of a treatment effect.
- pubmed-42570209
A total of 22 economic evaluations were included.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
A meta-analytic pooled estimate found teriparatide shortened overall time to fracture union compared with a control group, with a mean difference of -3·03 (95% CI -3·61 to -2·45).
Research context only—not evidence of a treatment effect.
- The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis.
Pooled analysis showed a significant reduction in time to union with use of teriparatide compared with a control (mean difference -3·03, 95% CI -3·61 to -2·45; Z=10·32; p<0·0001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Using micro-CT, the study observed a positive association between occlusal force and bone mass/density across all groups.
Research context only—not evidence of a treatment effect.
- Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.
Micro-CT revealed bone mass and density increased with higher occlusal force in all groups.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The background states teriparatide is used clinically in osteoporosis management with the goal of reducing fracture risk.
Research context only—not evidence of a treatment effect.
- The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis.
Bisphosphonates and teriparatide are used in the management of osteoporosis and reduction of fracture risk.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide refers to the 1-34 amino-acid fragment of parathyroid hormone (PTH).
Research context only—not evidence of a treatment effect.
- Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.
While intermittent PTH (1-34) (teriparatide) is an established treatment for osteoporosis
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is described as a recombinant fragment derived from parathyroid hormone (rPTH).
Research context only—not evidence of a treatment effect.
- Intein-mediated high-yield expression of recombinant teriparatide.
Teriparatide, a recombinant fragment of parathyroid hormone (rPTH), is employed in the treatment of osteoporosis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Across all examined teriparatide materials, a shared set of impurities was detected: one isomeric impurity and three oxidation-related impurities.
Research context only—not evidence of a treatment effect.
- pubmed-42312586
One isomer and three oxidation impurities were found co-existing in all the study materials.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Recombinant teriparatide is described as an anabolic agent, meaning it promotes bone formation.
Research context only—not evidence of a treatment effect.
- Teriparatide: a review of its use in osteoporosis.
Recombinant teriparatide (Forteo; Forsteo) is an anabolic (bone forming) agent.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In ChEMBL, teriparatide is indexed under the identifier CHEMBL525610.
Research context only—not evidence of a treatment effect.
- TERIPARATIDE
ChEMBL ID: CHEMBL525610
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is a recombinant analog of parathyroid hormone.
Research context only—not evidence of a treatment effect.
- Assessment of Teriparatide's Effect on Post-operative Functional Outcome and Fracture Healing.
Teriparatide, a recombinant parathyroid hormone analog, demonstrates anabolic bone formation capacity through enhanced osteoblastic activity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is identified as the 1-34 fragment of parathyroid hormone (PTH), i.e., PTH 1-34.
Research context only—not evidence of a treatment effect.
- The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review.
Parathyroid hormone (PTH; teriparatide, PTH 1-34)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
ChEMBL’s preferred name field for CHEMBL525610 is TERIPARATIDE.
Research context only—not evidence of a treatment effect.
- TERIPARATIDE
Preferred name: TERIPARATIDE
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is a recombinant parathyroid hormone (PTH) therapy used in osteoporosis treatment.
Research context only—not evidence of a treatment effect.
- pubmed-42590191
Teriparatide, a recombinant form of parathyroid hormone used for the treatment of osteoporosis
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Palopegteriparatide is characterized as a prodrug form of parathyroid hormone fragment PTH (1,34).
Research context only—not evidence of a treatment effect.
- Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update.
One such agent, palopegteriparatide, a prodrug of PTH (1,34), has shown promise to be the first hormone replacement therapy for hypoPT.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The quantification approach included an external standard method and multiple (four) quantitative scenarios to improve accuracy for structurally related impurities.
Research context only—not evidence of a treatment effect.
- pubmed-42312586
external standard method and four quantitative scenarios were adopted to achieve an accurate quantification of structurally related impurities in the TPT study materials.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The experimental design compared impurity profiles across teriparatide materials from chemical synthesis versus recombinant synthesis reference standards.
Research context only—not evidence of a treatment effect.
- pubmed-42312586
One commercially available chemical synthesis material and two recombinant synthesis pharmacopoeia reference standards were used to investigate the TPT impurity profiles in this study.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
To compare impurity profiles, the investigators analyzed one commercially available chemically synthesized teriparatide material and two recombinant-synthesis pharmacopoeia reference standards.
Research context only—not evidence of a treatment effect.
- pubmed-42312586
One commercially available chemical synthesis material and two recombinant synthesis pharmacopoeia reference standards were used to investigate the TPT impurity profiles in this study.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is stated to have anabolic bone-forming capacity via enhanced osteoblastic activity.
Research context only—not evidence of a treatment effect.
- Assessment of Teriparatide's Effect on Post-operative Functional Outcome and Fracture Healing.
Teriparatide, a recombinant parathyroid hormone analog, demonstrates anabolic bone formation capacity through enhanced osteoblastic activity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is described as having an anabolic mechanism of action, meaning it promotes bone building rather than only reducing bone breakdown.
Research context only—not evidence of a treatment effect.
- Teriparatide: a review.
The mechanism of action of teriparatide is unique in that it possesses anabolic properties and therefore builds bone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Polymer phase separation control is reported to drive preferential localization of teriparatide into the microsphere core (a formulation-structure mechanism).
Research context only—not evidence of a treatment effect.
- pubmed-41950644
Through precise regulation of polymer phase separation, teriparatide is preferentially localized within the microsphere core.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The source characterizes teriparatide (PTH 1-34) as osteoanabolic and notes recognized effects on bone remodeling processes.
Research context only—not evidence of a treatment effect.
- The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review.
Parathyroid hormone (PTH; teriparatide, PTH 1-34) is an established osteoanabolic agent with recognized impacts on bone remodelling.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion attributes iPTH’s protection against periodontitis-induced alveolar bone loss to dependence on regulatory T cells, implicating immunomodulatory control by Tregs as a key mechanism.
Research context only—not evidence of a treatment effect.
- Intermittent parathyroid hormone (1-34) ameliorates periodontitis via Treg-dependent immunomodulation of the Treg/Th17 axis.
iPTH ameliorates periodontitis-induced alveolar bone loss through a Treg-dependent mechanism.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The evidence identification used multiple bibliographic databases with a search end date of October 2024.
Research context only—not evidence of a treatment effect.
- pubmed-42570209
A comprehensive literature search was conducted in PubMed, Scopus, Embase, and Web of Science up to October 2024.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The conclusion highlights regulation of the balance between regulatory T cells (Treg) and Th17 responses as a central immunomodulatory mechanism explaining iPTH’s efficacy in the studied context.
Research context only—not evidence of a treatment effect.
- Intermittent parathyroid hormone (1-34) ameliorates periodontitis via Treg-dependent immunomodulation of the Treg/Th17 axis.
This identifies the immunomodulation of the Treg/Th17 axis as a pivotal mechanism underlying iPTH's efficacy, highlighting its potential as a host-modulating therapy for periodontitis.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Methodological quality appraisal of eligible economic studies used the QHES instrument.
Research context only—not evidence of a treatment effect.
- pubmed-42570209
Studies that met the inclusion criteria were assessed using the Quality of Health Economic Studies (QHES) checklist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The study fused a gp41-1 mutant (noted for high traceless cleavage) to teriparatide as part of an intein-mediated strategy to improve recombinant production.
Research context only—not evidence of a treatment effect.
- Intein-mediated high-yield expression of recombinant teriparatide.
In this study, a gp41-1 mutant with demonstrated high traceless cleavage activity was fused to teriparatide to address these issues and develop an intein-mediated high-yield expression system.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Teriparatide is described as a PTH-mimetic that regulates calcium and phosphate metabolism in both bone and kidney.
Research context only—not evidence of a treatment effect.
- IUPHAR ligand commentary
Teriparatide mimics the activity of endogenous PTH to regulate calcium and phosphate metabolism in bone and kidney.
Safety + tolerability
Risks, organized for scanning.
Contraindications
- Serious hypersensitivity; avoid in patients with increased baseline osteosarcoma risk as described in labeling
Common effects
- Nausea
- Joint aches
- Pain
- Transient dizziness
Serious risks
- Osteosarcoma risk considerations
- Hypercalcemia
- Orthostatic hypotension
- Urolithiasis considerations
- Medication/device errors
Structured from current product labeling [1]Regulatory labelForteo prescribing informationDailyMed label updated June 2025 for teriparatide injection.
Products + regulatory context
Same ingredient. Different records.
| Product | Form | Profile scope | Record |
|---|---|---|---|
| Forteo | Daily subcutaneous injection | Osteoporosis treatment in specified high-risk populations. | [1]Regulatory labelForteo prescribing informationDailyMed label updated June 2025 for teriparatide injection. |
| Bonsity | Daily subcutaneous injection | Teriparatide product with its own device and label. | [8]Published evidence snapshotThese highlights do not include all the information needed to use BONSITY safely and effectively. See full prescribing information for BONSITY.BONSITY (teriparatide injection), for subcutaneous useInitial U.S. Approval: 1987dailymed · T1 |
| Teriparatide injection | Daily subcutaneous injection | Approved generic/alternative presentations vary by manufacturer. | [7]Published evidence snapshotThese highlights do not include all the information needed to use TERIPARATIDE INJECTION safely and effectively. See full prescribing information for TERIPARATIDE INJECTION.TERIPARATIDE injection, for subcutaneous useInitial U.S. Approval: 1987dailymed · T1 |
Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.
Administration, interactions + monitoring
The practical clinical context.
- Administration boundary
- Once-daily subcutaneous injection using a product-specific device; initial doses may be given where the patient can sit or lie down if orthostatic symptoms occur. [1]Regulatory labelForteo prescribing informationDailyMed label updated June 2025 for teriparatide injection.
Research status + gaps
What still needs better answers.
1359 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (819), assurance_score_below_0.72 (420), current_regulatory_source_required (258), evidence_scope (362), extraction_ambiguity (869), extraction_confidence_not_high (8), high_risk_requires_regulatory_or_two_independent_sources (511), no_direct_support (1228), proposal_not_staged (21)
How Peplexicon reads evidence
- Authority
- What kind of source is making the statement?
- Independence
- Do multiple citations represent separate studies—or the same evidence repeated?
- Directness
- Does the population, product, dose, outcome, and time horizon match the claim?
- Consistency
- Do credible sources support, qualify, or contradict one another?
References + discovery
Open the records yourself.
- 1Regulatory labelForteo prescribing informationOpen ↗
DailyMed label updated June 2025 for teriparatide injection.
- 2Literature indexEvery PubMed result for teriparatideOpen ↗
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
- 3Trial registryEvery registered study for teriparatideOpen ↗
Live ClinicalTrials.gov search, including completed, active, and historical records.
- 4Chemical recordteriparatide chemical recordOpen ↗
PubChem compound search from the National Library of Medicine.
- 5Published evidence snapshotChEMBL activities for CHEMBL525610Open ↗
chembl-activities · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 6Published evidence snapshotTERIPARATIDEOpen ↗
chembl-molecule · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 7Published evidence snapshotThese highlights do not include all the information needed to use TERIPARATIDE INJECTION safely and effectively. See full prescribing information for TERIPARATIDE INJECTION.TERIPARATIDE injection, for subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2025-05-27 · retrieved 2026-08-18T22:04:36Z - 8Published evidence snapshotThese highlights do not include all the information needed to use BONSITY safely and effectively. See full prescribing information for BONSITY.BONSITY (teriparatide injection), for subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2025-06-01 · retrieved 2026-08-25T08:39:52Z - 9Published evidence snapshotThese highlights do not include all the information needed to use TERIPARATIDE INJECTION safely and effectively. See full prescribing information for TERIPARATIDE INJECTION.TERIPARATIDE injection, for subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2026-03-12 · retrieved 2026-08-21T17:03:42Z - 10Published evidence snapshotThese highlights do not include all the information needed to use FORTEO safely and effectively. See full prescribing information for FORTEO.FORTEO (teriparatide injection), for subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2026-08-03 · retrieved 2026-08-21T17:03:42Z - 11Published evidence snapshotThese highlights do not include all the information needed to use Teriparatide Injection safely and effectively. See full prescribing information for Teriparatide Injection.Teriparatide Injection, for subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2025-06-16 · retrieved 2026-08-25T08:39:52Z - 12Published evidence snapshotThese highlights do not include all the information needed to use TERIPARATIDE INJECTION safely and effectively. See full prescribing information for TERIPARATIDE INJECTION.TERIPARATIDE injection, for subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2024-09-01 · retrieved 2026-08-25T08:39:52Z - 13Published evidence snapshotThese highlights do not include all the information needed to use TERIPARATIDE INJECTION safely and effectively. See full prescribing information for TERIPARATIDE INJECTION.TERIPARATIDE injection, for subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2025-12-22 · retrieved 2026-08-25T08:39:52Z - 14Published evidence snapshotThese highlights do not include all the information needed to useTERIPARATIDE INJECTIONsafely and effectively. See full prescribing information forTERIPARATIDE INJECTION.TERIPARATIDE injectionfor subcutaneous useInitial U.S. Approval: 1987Open ↗
dailymed · T1
Published 2026-03-27 · retrieved 2026-08-18T22:04:31Z - 15Published evidence snapshotTeriparatide or alendronate in glucocorticoid-induced osteoporosis.Open ↗
doi · T2
Published 2007-11-01 · retrieved 2026-09-08T21:45:48Z - 16Published evidence snapshotForsteo | European Medicines Agency (EMA)Open ↗
ema · T6
Published 2026-08-18 · retrieved 2026-08-18T22:04:44Z - 17Published evidence snapshotTeriparatide Sun | European Medicines Agency (EMA)Open ↗
ema · T6
Published 2026-08-18 · retrieved 2026-08-18T22:04:39Z - 18Published evidence snapshotIUPHAR ligand commentaryOpen ↗
iuphar-comments · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 19Published evidence snapshotteriparatideOpen ↗
iuphar-ligand · T6
Published 2026-08-21 · retrieved 2026-08-21T17:03:42Z - 20Published evidence snapshotTeriparatide: a review.Open ↗
pubmed · T3
Published 2004-06-01 · retrieved 2026-09-09T18:01:36Z - 21Published evidence snapshotParathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.Open ↗
pubmed · T3
Published 2005-08-01 · retrieved 2026-09-09T23:03:13Z - 22Published evidence snapshotTeriparatide: a review of its use in osteoporosis.Open ↗
pubmed · T3
Published 2008-01-01 · retrieved 2026-09-09T23:03:14Z - 23Published evidence snapshotADULT HYPOPHOSPHATASIA TREATED WITH TERIPARATIDE: REPORT OF 2 PATIENTS AND REVIEW OF THE LITERATURE.Open ↗
pubmed · T3
Published 2016-08-01 · retrieved 2026-09-09T23:03:14Z - 24Published evidence snapshotA clinical study on the effects of teriparatide and denosumab on bone metabolism and gut microbiota in osteoporotic fracture patients.Open ↗
pubmed · T3
Published 2026-04-08 · retrieved 2026-09-09T08:36:24Z - 25Published evidence snapshotpubmed-41950644Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 26Published evidence snapshotRomosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study.Open ↗
pubmed · T3
Published 2026-04-10 · retrieved 2026-09-09T08:36:24Z - 27Published evidence snapshotAnabolic effect of parathyroid hormone (1-34) to prevent ovariectomy induced bone loss is attenuated in Col1A1-cre floxed monocyte chemotactic protein 1 (MCP1, CCL2) mice.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-21T17:03:42Z - 28Published evidence snapshotTeriparatide in Two Patients With Mucopolysaccharidosis Type IVB.Open ↗
pubmed · T3
Published 2026-05-01 · retrieved 2026-09-09T08:36:24Z - 29Published evidence snapshotRomosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.Open ↗
pubmed · T3
Published 2026-04-17 · retrieved 2026-09-09T08:36:24Z - 30Published evidence snapshotRomosozumab Versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: An Overview of Systematic Reviews With Direct and Indirect Meta-Analyses.Open ↗
pubmed · T2
Published 2026-04-01 · retrieved 2026-09-09T08:36:24Z - 31Published evidence snapshotEffects of romosozumab on bone strength around a pedicle screw as evaluated by biomechanical computed tomography-based virtual stress tests in postmenopausal women.Open ↗
pubmed · T2
Published 2026-05-01 · retrieved 2026-09-09T08:36:24Z - 32Published evidence snapshotA Comparison Between Bisphosphonates and Teriparatide in the Treatment of Postmenopausal Osteoporosis: A Systematic Review.Open ↗
pubmed · T3
Published 2026-04-01 · retrieved 2026-09-09T08:36:24Z - 33Published evidence snapshotDelayed diagnosis of mucopolysaccharidosis type I in a patient with spinopelvic instability, short stature, and skeletal dysplasia.Open ↗
pubmed · T3
Published 2026-06-01 · retrieved 2026-09-05T08:43:42Z - 34Published evidence snapshotPostpartum timing of teriparatide initiation and BMD response in pregnancy- and lactation-associated osteoporosis: an observational study.Open ↗
pubmed · T3
Published 2026-05-11 · retrieved 2026-09-05T08:43:42Z - 35Published evidence snapshotAssessment of Teriparatide's Effect on Post-operative Functional Outcome and Fracture Healing.Open ↗
pubmed · T3
Published 2026-05-01 · retrieved 2026-09-09T08:36:24Z - 36Published evidence snapshotTeriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.Open ↗
pubmed · T2
Published 2026-07-14 · retrieved 2026-08-25T08:39:52Z - 37Published evidence snapshotAltered Intracellular Trafficking as a Mechanism for Prolonged Duration of G Protein-Coupled Receptor Activation.Open ↗
pubmed · T3
Published 2026-06-03 · retrieved 2026-09-05T08:43:42Z - 38Published evidence snapshotContinuous subcutaneous recombinant PTH(1-34) infusion improves serum calcium and phosphate homeostasis in children with autosomal dominant hypocalcemia type 1 refractory to standard-of-care treatment.Open ↗
pubmed · T3
Published 2026-04-30 · retrieved 2026-09-09T08:36:24Z - 39Published evidence snapshotManagement of osteoporosis in older men: a systematic review of randomized trials of pharmacological and non-pharmacological strategies.Open ↗
pubmed · T2
Published 2026-05-22 · retrieved 2026-09-05T08:43:42Z - 40Published evidence snapshotSynergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.Open ↗
pubmed · T3
Published 2026-05-22 · retrieved 2026-09-05T08:43:42Z - 41Published evidence snapshotComparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis.Open ↗
pubmed · T2
Published 2026-01-01 · retrieved 2026-09-02T08:48:30Z - 42Published evidence snapshotEfficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III study.Open ↗
pubmed · T3
Published 2026-05-01 · retrieved 2026-09-05T08:43:42Z - 43Published evidence snapshotBone Bridge Effect for the Treatment of Acute Osteoporotic Vertebral Compression Fractures: A Multistrategic Approach Using an Anabolic Agent.Open ↗
pubmed · T3
Published 2026-06-01 · retrieved 2026-09-05T08:43:42Z - 44Published evidence snapshotThe impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects: A systematic review.Open ↗
pubmed · T2
Published 2026-06-01 · retrieved 2026-09-05T08:43:42Z - 45Published evidence snapshotPre-teriparatide anti-osteoporosis medication therapy and fracture-related hospitalization in patients at very high fracture risk.Open ↗
pubmed · T3
Published 2026-06-02 · retrieved 2026-09-05T08:43:42Z - 46Published evidence snapshotThe effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis.Open ↗
pubmed · T2
Published 2026-05-01 · retrieved 2026-09-09T08:36:24Z - 47Published evidence snapshotParathyroid hormone enhances appetite and fails to reduce adiposity in ob/ob mice.Open ↗
pubmed · T3
Published 2026-06-03 · retrieved 2026-09-05T08:43:42Z - 48Published evidence snapshotpubmed-42235813Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 49Published evidence snapshotIntermittent parathyroid hormone employs autonomous and non-autonomous mechanisms to drive osteogenesis from Ebf3-expressing skeletal progenitor cells.Open ↗
pubmed · T3
Published 2026-05-26 · retrieved 2026-09-05T08:43:42Z - 50Published evidence snapshotChange in vBMD of Combination Therapy of Teriparatide and Denosumab in Osteoporosis at 18 Months: How Much Difference Does It Make on Spine vBMD?Open ↗
pubmed · T3
Published 2026-06-01 · retrieved 2026-09-05T08:43:42Z - 51Published evidence snapshotPotent and biased agonists of class B1 GPCRs from a heterochiral design strategy.Open ↗
pubmed · T3
Published 2026-09-01 · retrieved 2026-09-01T08:37:10Z - 52Published evidence snapshotpubmed-42312586Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 53Published evidence snapshotEvaluation of teriparatide as a promoter of mandibular fracture healing: An observational clinical study.Open ↗
pubmed · T3
Published 2026-05-20 · retrieved 2026-09-05T08:43:42Z - 54Published evidence snapshotUse of Teriparatide for Treatment of a 3-Year-Old Child with an Activating Calcium-Sensing Receptor Mutation.Open ↗
pubmed · T3
Published 2026-07-10 · retrieved 2026-08-28T12:18:09Z - 55Published evidence snapshotInfluence of bisphosphonate pretreatment on bone mineral density gains and fracture outcomes with teriparatide: A systematic review and meta-analysis.Open ↗
pubmed · T3
Published 2026-07-15 · retrieved 2026-08-25T08:39:52Z - 56Published evidence snapshotPeptide Therapeutics in Orthopaedics: Current Evidence and Future Directions.Open ↗
pubmed · T3
Published 2026-09-02 · retrieved 2026-09-05T08:43:42Z - 57Published evidence snapshotTeriparatide Therapy in Children with Hypoparathyroidism: A Systematic Review and Meta-Analysis.Open ↗
pubmed · T2
Published 2026-07-25 · retrieved 2026-08-21T17:03:42Z - 58Published evidence snapshotPharmacological effects of PTH1R agonists on jaw bone fracture, periodontitis, orthodontic treatment and MRONJ: a view from dosing regimen settings.Open ↗
pubmed · T3
Published 2026-07-26 · retrieved 2026-08-21T17:03:42Z - 59Published evidence snapshotIntra-Articular Injection of Parathyroid Hormone (1-34) Enhances Meniscal Healing at the Site of a Radial Tear in the Rabbit Medial Meniscus.Open ↗
pubmed · T3
Published 2026-07-12 · retrieved 2026-08-25T08:39:52Z - 60Published evidence snapshotStrontium Treatment Potentiates Bone Anabolic Action of Intermittent PTH in Ovariectomized Rats.Open ↗
pubmed · T3
Published 2026-07-28 · retrieved 2026-08-21T17:03:42Z - 61Published evidence snapshotIntein-mediated high-yield expression of recombinant teriparatide.Open ↗
pubmed · T3
Published 2026-07-30 · retrieved 2026-08-21T17:03:42Z - 62Published evidence snapshotpubmed-42570209Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 63Published evidence snapshotpubmed-42579011Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 64Published evidence snapshotPerioperative teriparatide in adult spinal deformity: a retrospective comparative cohort study.Open ↗
pubmed · T3
Published 2026-08-01 · retrieved 2026-08-21T17:03:42Z - 65Published evidence snapshotpubmed-42584962Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 66Published evidence snapshotRomosozumab Versus Teriparatide for Fracture Prevention, Cardiovascular Events, and Mortality in Osteoporosis: A Propensity Score-Matched Real-World Cohort Study.Open ↗
pubmed · T3
Published 2026-07-28 · retrieved 2026-08-21T17:03:42Z - 67Published evidence snapshotpubmed-42590191Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-17T23:10:15Z - 68Published evidence snapshotIntermittent parathyroid hormone (1-34) ameliorates periodontitis via Treg-dependent immunomodulation of the Treg/Th17 axis.Open ↗
pubmed · T3
Published 2026-01-01 · retrieved 2026-08-21T17:03:42Z - 69Published evidence snapshotPerioperative Anabolic Osteoporosis Pharmacotherapy is Associated with Lower Rates of Proximal Junctional Kyphosis After Adult Spinal Deformity Surgery: A Systematic Review and Meta-Analysis.Open ↗
pubmed · T3
Published 2026-08-17 · retrieved 2026-08-21T17:03:42Z - 70Published evidence snapshotPalopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update.Open ↗
pubmed · T3
Published 2026-09-01 · retrieved 2026-08-21T17:03:42Z - 71Published evidence snapshotRestoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw.Open ↗
pubmed · T3
Published 2026-08-19 · retrieved 2026-08-21T17:03:42Z - 72Published evidence snapshotTeriparatide treatment of osteoporosis in solid organ transplant recipients-a single-center experience.Open ↗
pubmed · T3
Published 2026-09-02 · retrieved 2026-09-09T08:36:24Z